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Rationale: During the last decennium a more focused attention has been directed to the presence of chronic inflammation 
in cardiovascular diseases (CVD), but mainly to the high impact that this one has in generating and fastening the atherosclerotic 
process. 
Objective: To highlight the causal relationship between periodontal diseases (PD) and CVD.  
One of the most important chronic inflammations, present in the modern societies in the vast majority of the population, is 
represented by the periodontal diseases (PD). Both types of diseases are characterized by a high and continuously increasing 
prevalence. 
It is now clear that they share some common risk factors, but it would be of great interest, not only for a scientific purpose, but also 
from a possible health benefit, as PD can be prevented and treated efficiently, to prove that there is a causal link between these two 
pathologies. 
Methods: We will present a review of the actual data concerning their relationship. 
Discussion: The study of this causal relationship is made more difficult due to the increased utilization, due to the guides’ 
recommendations of the calcium antagonists (CA) in treating CVD.  
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Abreviations: AE = adverse effect; AMI = acute myocardial infarction; CA = calcium antagonists; CHD = coronary heart 
disease; COI = chronic oral infection; CsA = cyclosporine A; CVD = cardio-vascular diseases; DM = diabetes mellitus; 
DNA = deoxyribonucleic acid; GH = gingival hypertrophy; GO = gingival overgrowth; hs-CRP = high-sensitivity C reactive 
protein; IL = interleukine; ICAM = intracellular adhesion molecule; JE/MCP-1 = macrophage chemotactic protein; LPS – 
lipopolisaccharides; MIP-2 = macrophage inflammatory protein-2; MMP = matrix metalloproteinases; mRNA = 
messenger-ribonucleic acid; NOS = nitric oxide synthase; PAI-1 = plasminogen activator inhibitor-1; PD = periodontal 
diseases; TIMP = tissue inhibitor of metalloproteinase; TNF = tumor necrosis factor; USA = United States of America; 
UFC = units forming cultures; WHO= World Health Organization. 
Epidemiologic links: PD-CVD 
The epidemiological link that exists between 
chronic oral infections (COI) and CVD has been largely 
demonstrated in the last 10 years. PDs are, undoubtedly, 
the most frequent type of COI [1-5]. 
The highest prevalence of PD and CVD is 
encountered in third age populations. During the last 
years calcium antagonists (CA) reached the class I, a 
level of evidence recommendation in treating coronary 
heart disease (CHD), the most fearful and most frequent 
expression of atherosclerosis. It is well known that 
cardiovascular disease is the single most common cause 
of death in the developed world and accounts for almost 
one million fatalities each year in United States alone [3]. 
Nearly half of these deaths result from coronary artery 
disease, another 20% from stroke [3]. 
So, the problem became more complicated: first 
to demonstrate a causal link between PD and CVD and, 
then, to find if CA, although they have a benefic effect in 
CHD, could have a deleterious effect on the periodontium. 
We have already mentioned many 
epidemiological proofs concerning PD and CVD [1-5]. 
In order to prove a causative association 
between the two types of pathologies it would be 
necessary to do that by properly designed trials. Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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However, using hard endpoints in this kind of 
trials would mean impressive costs and a very long 
duration. That is why, maybe the surrogate end-points 
and some surrogate variables that are considered to have 
a significant predictable value for future cardio-vascular 
events: high sensitivity C-reactive protein (hs-CRP), 
homocysteine (although during the last 2 years their 
predictive value for future cardio-vascular events have 
been doubted), plasma fibrinogen, plasminogen activator 
inhibitor-1 (PAI-1), D-dimers, lipoproteins [1,2]. 
The importance of this kind of trials, that have 
been already done, and that we will mention is underlined 
by the fact that they showed not only a significant 
association, but also a significant pathogenic, causative 
relationship between PD and CVD [3,4,5]. 
In the last assembly of the World Health 
Organization (WHO) it has been strongly advocated for a 
good oral health, for integrating the prevention and health 
promotion policies between oral and general health [6]. 
Just a year ago a workshop regarding the 
connections between PD and CVD was held in Madrid 
(Spain) [7]. 
We should also mention that good preventive 
health care is associated with many other benefits, of 
which the most important can be considered the quality of 
life (QOL). Also, in USA General Surgeon: “Oral health in 
America” is underlining the fact that oral health represents 
a fundamental part of the general health [8].  
 
Chronic infection: the main pathogenic connection 
Why is it so important to study PD? Because: 
they have in common a predominant 
infectious/inflammatory origin; they are very frequent 
diseases: between 20 and 50% of a general population 
have this kind of diseases; more than 85% in the third age 
population (in some developed countries)[9]; if we could 
demonstrate that PD represent an important and 
reversible risk factor for CVD, the importance of 
preventing and treating them would be tremendous, due 
to the fact that the significantly important and real 
reversible risk factors for CVD are not so many (and those 
already known would imply important changes in lifestyle, 
that not so many subjects would agree). 
PD are considered to be of multiple etiologies: 
the bacterial accumulation and their organization in the 
dental biological film represent the “ignition” phenomenon; 
the devastating factor, regarding the destruction of the 
deeper periodontal tissue (by the action of the large 
number of leukocytes that are accumulating in the gingival 
tissues) is considered the host-mediated cell-mediated 
immune response, mediated by large amounts of 
inflammatory mediators: cytokines-chemokines and matrix 
metalloproteinases (MMP)[10,11,12]. 
We must underline that MMP are involved in the 
immune pathogenic process of PD; they also include 
collagenase (that represents a reliable marker of the 
active disease when the plasmatic and salivary 
concentrations are significant). We could also use as a 
clear-cut edge a high concentration of collagenase, to 
make the difference between a simple gingival 
inflammation (gingivitis) and a very severe, with 
destructive potential PD. 
PD have the following risk factors: increasing 
age, specific periodontal pathogens: Porphyromonas 
gingivalis, Tanerella forsythia, Fusobacterium nucleatum, 
some ethnic minorities, low socio-economic status, male 
gender, stress, increased body weight, dyslipidaemia, 
hypertension, diabetes mellitus (DM), cigarette smokers, 
the last five common cardio-metabolic risk factors being 
associated with increased odds of prevalence of 
periodontitis. Important risk factors for PD are considered: 
poor oral hygiene; diabetes mellitus; immune depression. 
Concerning the risk factors of CVD, these ones 
have been classified as: conventional risk factors: 
smoking, hypertension, dyslipidaemia, insulin resistance 
and diabetes mellitus, lack of exercise, obesity; novel 
atherothrombotic risk factors: high sensitivity C-
reactive protein (hs-CRP) and other markers of 
inflammation, homocysteine and lipoprotein (a); 
thrombotic markers of risk: fibrinogen, D-dimers, 
abnormalities in intrinsic fibrinolysis. All these risk factors 
can have a common pathway that is represented by 
endothelial dysfunction and inflammation. 
In considering their possible causal relationship, 
we must start with some wrong beliefs, very common 
even in medical populations: an action that even a 
scientific authority as the American Academy of 
Periodontolgy can take: “Facts and fallacies about 
periodontal diseases”:  
 it is natural that dental loss appears with age 
increase: false – PD represent the main cause for 
edentations appearing before 35 years old; 
 the main cause for dental loss are cavities: false 
– in 1996 American Dental Association (Colgate survey) 
has demonstrated a 2:1 ratio in favor of PD; 
 those with PD generally have a poor hygiene: 
false – up to 30% of the general population is genetically 
susceptible of PD (they have a 6 times greater tendency 
for PD); 
 the oral health does not affect general health: 
false – PD are associated with: CVD, “small for date” 
newborns, prematurity, stroke, diabetes mellitus. 
 mucosal infection is a rather small, minor one: 
false – the mass of the tissue in the oral cavity equals the 
skin of the arms, from elbow to wrist; 
 bleeding of the gums is a natural phenomenon: 
false - bleeding is one of the most frequent signs of 
gingival disease; 
 gingival treatment is painful: false; 
 gingival diseases are easy to recognize, so that 
any dentist could see very reliable all the abnormalities; 
 because gingival infections are generated by 
microbial agents, one can use antibiotics for their Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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treatment: false – that create the great risk of selecting 
multi-resistant species; 
 pregnant women should skip their periodic dental 
controls, because it’s well known that their increase in 
dental mobility is only temporary: false – the diminished 
immunity during this period make mandatory a periodical 
periodontal control. 
Let us now return to the initiating process: 
anytime the local blood flow decreases, a common fact for 
both CVD and PD, a complex array of metabolic 
abnormalities results from an insufficient delivery of 
oxygen and nutrients combined with a diminished removal 
of waste products. The oxygen deprivation is a trigger for 
the activation of the clotting system; the tissue factor 
pathway represents the main trigger for the pro-coagulant 
mechanism. 
The normal endothelium is characterized by 
reduced, if any, presence of tissue factor, a fact that is 
necessary in order to maintain a normal blood flow. 
Oxygen deprivation is generating a rapid 
increase in tissue factor expression in the vessel wall, due 
to the rapid increase in tissue factor expression (by a 
prompt increase in the level of mRNA tissue factor). The 
hypoxia-induced expression of the gene is closely linked 
to a tissue factor promoter, this phenomenon being 
followed by: an increase of vascular permeability; a pro-
coagulant significant effect; an up-regulation of the cell 
adherence, of ICAM molecules and of the inflammatory 
mediators associated with leukocyte migration and 
activation, (the leukocytes have an important role in 
tissue damage, consequent to ischemia). 
Similarly, PAI-1, the cytokine interleukin (IL)-1β 
and chemokines macrophage inflammatory protein (MIP)-
2 and macrophage chemotactic protein (JE/MCP)-1 are 
up regulated by ischemia (all these molecules being 
linked to leukocyte-mediated tissue damage). 
The host-tissue response is characterized by a 
local accumulation of neutrophils, macrophages, different 
lymphoid cells, that will elicit, together with the adjacent 
host-tissue cells, an immune-inflammatory response, 
characterized by the release of different cytokines and 
prostanoids: IL-1, IL-6, IL-8, TNF-alpha, prostaglandin E2, 
different MMPs (these ones playing a crucial role in the 
destruction of the bone and of the connective tissue). 
Together with the fact that lipopolysaccharides 
(LPS) and other products of the Gram negative bacteria 
may stimulate, cytokine production; hypercoagulability; 
monocyte activation; liver activation, that will all have a 
direct or/and indirect effect on the vascular walls, 
generating endothelial dysfunction. 
Therefore, the mechanisms by which periodontal 
bacteria may contribute to CVD: blood platelet 
aggregation; enhanced low-density lipoproteins and 
cholesterol deposition in the arterial wall; direct invasion 
of the cardiac and vascular endothelium [13,14,15]. 
Regarding the different components of the 
immune process implied by the presence of PD, it is 
important to underline the following: 
MMP-8 can be defined as a collagenase found in 
the gingival tissue, with high values in the crevicular fluid 
during periodontal diseases. It is considered, together 
with IL-1β salivary level, a reliable marker of PD. MMP-8 
is the only proteinase that has the capacity of collagen I 
and III fragmentation, the main mechanism for the 
periodontal tissue destruction, so high levels of MMP-8 
are correlated with severe PD. A 3 times greater than 
normal concentration of MMP-8 can be used as 
diagnostic tool to differentiate a severe form of PD from a 
simple inflammation (gingivitis). 
An efficient periodontal treatment is followed by 
a normalization of these values [6]. More severe is the 
PD, higher are the values of MMP-1, MMP-2, MMP-3, 
MMP-8 and MMP-13 [10,11]. 
 
All the metalloproteinases play an important role in 
the immune response and in atherogenesis.  
Elevated levels of the extra-cellular matrix 
metalloproteinase inductor and of the tissue inhibitor of 
metalloproteinase (TIMP) in the gingival crevicular fluid 
participate in PD progression [6]. 
 
The periodontal microorganisms are generating the 
PD and are stimulating the host immune response. 
The first step of the answer to periodontal 
microorganisms is represented by an infiltrate of 
mononuclear cells in the gingival connective tissue. 
The second step is represented by the release, 
from these “recruited” macrophages and lymphocytes of 
pro-inflammatory cytokines and growth factors, as IL-1β, 
TNF-α, enabling MMP gene transcription. 
The fibroblasts, keratinocytes, macrophages, 
endothelial cells respond to catabolic products from the 
regulating MMP expression. 
The osteoblasts, activated by the same 
mechanism, induce bone desorption by fragmentation of 
the extracellular matrix constituents. An up-regulation of 
the cells adherence, ICAM molecules and of the 
mediators of inflammation is associated with leukocyte 
migration and activation. 
Given the large number of receptors, cofactors 
and mediators involved in vascular pathologies, it is 
important to understand where they are positioned in the 
host response cascades in which they participate. 
Although the bacteria are the main etiological 
agents, most of the tissue destruction occurs because of 
the host immuno-inflammatory response against the 
microbial challenge. This response is modulated by both 
genetic and environmental risk factors; there are 
evidences from twin studies that genetic factors explained 
a substantial proportion (almost 59%) of the variation in 
the severity and extent of periodontitis [16, 17].  Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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Inflammation is the initiating process of the atheroma 
formation and chronic infections including PD might 
influence systemic or vascular inflammation 
processes.  
This may also help understanding the complex 
interplay between recognized (i.e. increased age, male 
gender, dyslipidaemia, obesity,  cigarettes smoking, DM, 
etc.) and novel cardiovascular risk factors,  chronic 
infections and their associated inflammatory processes 
that can directly influence the physiopathology of 
atherosclerosis and thus alter CVD risk. 
The source of bacterial pathogens: caries and 
PDs, derives from the adhered bacterial populations to 
the tooth surfaces (biological films with a bacterial density 
of about 1011 UFC/mg). The bacterial communities 
present and adherent to the tooth surfaces are among the 
most complex existing in nature, due to the very complex 
ecosystems in the oral cavity, and especially in the 
periodontal environment, where a very dynamic co-
existence between pathogenic and saprophyte bacteria 
exists, on one side, and on the other side the host cell 
defences [18]. Patients with PD have a periodontal pocket 
that means an area especially prone for bacterial 
dissemination into the systemic circulation. Transient 
bacteriaemia has been reported after different preventive 
and therapeutic dental procedures: after scaling and root 
planning, after periodontal surgery, and dental extractions 
[19]. In addition, recent studies have suggested that 
everyday/common actions, such as chewing and tooth 
brushing contribute more significantly to the cumulative 
exposure of the vascular system to the oral bacteria [20]. 
Although most of the bacteriaemias are transient, it has 
long been recognized that bacteria in the blood stream 
may cause distant site infections.  
Several studies have demonstrated the presence 
of certain oral bacteria in atherosclerotic plaques and 
abdominal aortic aneurysms, in particular species 
implicated in the pathogenesis of periodontitis [21-23].  
The most common signs of this rather lack of 
symptoms condition are: gingival bleeding and swelling; 
these other ones represent the hallmark of the more 
advanced forms: gingival recession, drifting and mobility 
of the teeth, suppuration and are due to the progressive 
destruction of the dental supporting tissues, which finally 
leads to alveolar bone destruction up to the apex of the 
tooth, and even to the tooth exfoliation. 
The PD are defined by the anatomic destruction 
of the tissues that are sustaining the teeth, that appears 
after a pathological process. 
By using this definition, the severity is measured 
by the amplitude of the destruction. However, using tissue 
destruction as definition for PD is a way to look only to 
consequences, but no to the pathological process itself. 
Considering that PD are chronic infections that 
will lead to a systemic inflammation, they could be, and it 
would be a more scientific way of considering them, 
alternatively by the infectious burden or by their systemic 
inflammatory consequences. Of course, it is very clear 
that there is a direct relation between the amplitude of the 
destruction and the magnitude of the systemic 
manifestations of infection. 
When we are dealing with important tissue 
destruction and the presence of a periodontal pouch, 
there is a clear association with many markers of 
inflammation: hs-C protein, homocysteine, fibrinogen, 
PAI-1, D-dimers, proinflammatory cytokines plasmatic 
concentration [1,2,21- 26]. 
This inflammatory process represents the result 
of the interaction between pathological agents and the 
reactivity of the host [27-31]. 
For the beginning of a productive inflammatory 
process the pathogenic agents must act as an irritating 
factor, so that the periodontal marginal tissue reacts by a 
proliferative type of inflammation; in such type of 
inflammation the main process is represented by the 
reaction of the local tissue components that react by: 
hyperplasia, metamorphosis and mobilization, 3 stages in 
the defensive-adaptive process. 
The important changes in the periodontal chorion 
have an impact on the cement and alveolar bone.   
For the aim of this review, it is very important to 
underline that we are dealing with a chronic infection, 
leading to systemic inflammation. Considering PD this 
way, we could alternatively define them by the infection 
load or by the systemic inflammatory consequences, thus 
dealing more with the pathophysiological process than 
with the secondary destruction [32]. 
Investigating 657 subjects: the following 
microorganisms have been proved to be present in the 
dental film and in atherosclerotic lesion: Actinobacillus 
actinomycetem comitans, Porphyromonas gingivalis, 
Tannerella forsythia, Treponema denticola. It has also 
been proved that they are connected with intima-media 
thickness ratio and with hs-CRP levels.  
Although the dental plaque is by far the most 
common cause for gingivitis, many other factors can 
contribute to worsening the condition: drugs: 
antidepressants, those used for flu symptomatic treatment 
– they are decreasing the salivary secretion (generating 
xerostomia and severely decreasing the auto-cleaning 
capacity of the oral cavity); antiepileptic medication, 
calcium antagonists (CA), immune-depressing drugs 
(Cyclosporine A – Cs A); erithromycine, claritromycine, 
metronidazole, ketoconazole; viral and fungal 
infections; other diseases/conditions: pemphigus, 
pemphigoid; hormonal disturbances/ modifications 
(pregnancy, as an example); deficient nutrition: in 
calcium, C and B vitamins. 
 
Benefits and adverse effects of CA 
Old people commonly have many co-morbidities, 
each of them requiring one or more drugs [33]. Adverse 
reactions are more frequent in elderly population, due to a 
variety of reasons, but most frequently due to Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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polipragmasia: the risk is 6% for 1 drug; 50% for 5 drugs; 
100% for those taking more than 8 drugs. Moreover, this 
can generate other problems: the medical conditions that 
deserve medication; the effect of these 
conditions/medications on the healing capacity; the 
impact of these medications on the usual treatment 
schemes of the dentist. 
Calcium antagonists (CA) exert their effect by 
inhibiting the Ca++ influx by the specialized channels, real 
pharmacologic receptors. 
Their increasing use is explained by the benefic 
effects they have: to inhibit the contraction of the 
myocardial fibers; to depress the excitation generating the 
slow potentials; to relax smooth muscle fibers, especially 
the vascular ones, an effect that explains their first 
successfully utilization: in treating hypertension; but, 
nowadays they are increasingly used in treating CHD 
(class I recommendation, a level of evidence) where, by 
influencing the inward calcium current they can diminish 
platelet activation, the vascular contraction, the activity of 
endothelial cells, the monocytes invasion, the “foam cells” 
appearance, so that they can reduce the development of 
new atherosclerotic lesions. 
All the following are benefic actions in treating 
CHD: the direct and benefic effect on the endothelial 
function; the prevention of the noxious action of the 
endothelial mediators; to act as substitutes for the 
deficient endothelial factors; offers vascular protection by 
increasing NO-formation in the endothelial cells, 
ameliorating endothelial function. 
In stable angina, AC are: diminishing the effort-
induced vasoconstriction; reducing post-load by reducing 
blood pressure; diminishing the increase in cardiac 
frequency effort-induced and diltiazem and verapamil 
have a negative inotropic effect. 
Nifedipine was the first representative of the 
class of drugs that proved to have a protective effect for 
the cardiac cells from apoptosis, after acute myocardial 
infarction (AMI). The most frequent adverse effect (AE) 
that is associated with AC is represented by gingival 
overgrowth (GO), or after different authors gingival 
hypertrophy (GH). 
Gingival hyperplasia is a wrong denomination, 
since it’s not an increased number of cells, but an 
increase of the volume of the extra-cellular tissue. We 
prefer to use the term of GO because the volumetric 
increase of the gingival tissue is due to an increase of the 
amount of extra-cellular gingival macromolecules and the 
appearance of a great number of inflammatory cells. 
Inflammation of the gingival tissue from the 
bacterial plaque and the subsequent development of 
gingival crevicular fluid may allow sequestration of the 
CA, thus predisposing the tissue to a localized, toxic 
effect and to the development of GO. 
GO can be observed after a few weeks or after a 
few years from the beginning of the treatment, being 
reversible after interruption of the drug that is generating 
her, a fact that underlines the necessity of periodic, 
specialized examinations, because the real definition of 
GO is represented by the increase, with more than 1 
mm of the inter-dental papilla (even in an isolated 
space). 
The overgrown tissue has a lobulated /granular 
aspect. 
GO is aggravated by gingival inflammation and 
by a poor oral hygiene. 
We must mention that oral surgeons have made 
the first observations about this AE of CA [34,35]. 
For a definite diagnostic it is mandatory to 
include all the following: medical and dental history, 
including a summary of medical (drug) therapy; detailed 
examination of the teeth, of the periodontium, of the head 
and of the neck; photographs of the GO; dental X-ray; 
different blood tests; tissue biopsies or/and gingivectomy 
[36]. 
The number of fibroblasts (together considered: 
dead or functional) obtained from a normal gingival tissue 
has increased, the cellular death being inhibited by 
nifedipine, similar effect, concentration-dependent being 
obtained for: nicardipine, diltiazem, verapamil. 
Fibroblasts from nifedipine-induced fibrotic 
gingival hyperplastic epithelium, with elongated, branched 
rete pegs, have been characterized with respect to 
several cellular functions, which could contribute to the 
characteristic clinical overgrowth of the gingival: collagen 
synthesis and breakdown; glycosaminoglican production; 
fibronectin synthesis; proliferation. 
The data suggested that nifedipine affects the 
metabolism of fibroblasts derived not only from gingival, 
but also from other collective connective tissues. 
Thus, nifedipine responder cells are present in 
tissue other than gingival. 
There was an inverse relationship between in 
vivo tissue levels of IL-1 beta and in vivo responsiveness 
to nifedipine of fibroblasts derived from that tissue. 
Nifedipine-induced overgrowth of connective 
tissues, other than gingival, probably does not occur 
because of the reliability slow rate of collagenous protein 
synthesis by resident fibroblasts or because of alterations 
in collagen deposition / desorption within susceptible 
tissues produced by nifedipine on collagenase synthesis. 
The gingival epithelium is para-keratinized and 
exhibit elongated rete pegs. The underlying connective 
tissue comprised dense collagen fibers and the 
inflammatory cells, which were present in the connective 
tissue, were mainly plasma cells and lymphocytes. 
Nitric oxide synthase (NOS) induction has been 
completely prevented by incubation with nifedipine and 
the cellular death induced by LPS. 
Adherence and LPS-stimulated macrophage-
induced death of fibroblasts can be the mechanism of GO 
during chronic treatment with CA [37]. 
GO induced by nifedipine is characterized by an 
accumulation of collagen components in the gingival Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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connective tissue and epithelial hyperplasia with 
prolonged and branched rete pegs, that are penetrating in 
the connective tissue, the epithelial layer being thickened, 
acantotic, parakeratozic. 
Nifedipine, as the majority of CA induces 
alterations of the intracellular level of calcium in the 
gingival cells and can induce local inflammatory factors 
that are taking the place of collagen of the connective 
tissue, thus generating GO. 
CA have functional connections: nutritional 
synergy with folic acid, L-carnitine, different supplements 
that are diminishing the performance of the drugs: vitamin 
D, calcium, magnesium. 
GO can determine speech difficulties, 
mastication difficulties, dental eruption difficulties, 
esthetic disturbances. 
The marginal gingival tissue begins to have an 
excessive growth, especially at the anterior margin and 
could finally completely cover the occlusal surface of the 
teeth, creating major chewing problems. 
By electron microscopy, one can see the 
disappearance of the cellular bonds, the cellular 
exfoliation, and the fact that the normal honeycomb 
structure formed by the pits is disturbed [38,39]. 
Other gingival surfaces presented many round, 
oval or dome-like shapes that were replacing some micro-
bridges: parallel, reticular, having the shape of some 
fingerprints. 
The terminal differentiation of epithelial 
keratinocytes has been proposed as a specialized form of 
programmed cellular death (apoptosis). 
A loss of cellular adherence does not have as a 
result the beginning of apoptotic destruction of DNA, but 
an increased sensitivity of the cells to this fact, that was 
triggered by calcium [38,39]. 
This susceptibility appeared in parallel with the 
irreversible loss of the growing potential, volucrine 
accumulation (they are becoming competent for the 
apoptosis induced by calcium). 
Nifedipine determined an increase of the number 
of lymphocytes, and their number diminished after 
periodontal specialized treatment. 
Nifedipine determined GO in 5 - 39% [40-46] of 
subjects, the main factors influencing GO are the duration 
of the drug treatment (more than 4 years); the presence of 
the gingival inflammation; the severity of the gingival 
inflammation (the greatest inflammatory scores); male 
gender. 
Those with the highest inflammatory scores and 
those who had a longer than 4 years duration of the 
treatment, had an increased tendency for a higher 
incidence and severity of GO. 
Nifedipine increased the number of cells by 
increasing cellular proliferation; increased timeline uptake; 
increased the protein synthesis as a marker, the 
glucosamine uptake); increased the viability of the cells 
(as a marker, the LDH liberation). The results of long 
duration treatments showed an inhibition of proteoglicans 
synthesis. 
GO was more significantly present: in the inter-
dental papilla of the oral anterior region; the tissue is firm 
and pale, with a normally stippled pattern, and with a 
histopatologic aspect: a conspicuous increase of fibrous 
connective tissue; an inflammatory infiltrate; the presence 
of the hyperplasia of the underlying epithelium. 
It has been suggested that the fine regulated 
balance between extra-cellular matrix synthesis and 
degradation may be disrupted, resulting in an 
accumulation of excess connective tissue components 
within the gingival tissue. 
All the studies [48-52] showed a directly 
proportional relationship between the degree of 
inflammation and apoptosis; a strong inversely 
proportional trend between the degree of inflammation 
and the numbers of cells undergoing mitosis. 
These data suggest that epithelial cell 
proliferation and viability are inversely associated with the 
degree of gingival inflammation, once a putative 
“adaptative threshold” is exceeded. 
Fibroblasts derived from the overgrown tissue 
exhibit a level of protein synthetic activity approximately 
twice that of comparable cells obtained from controls: 
20% of the protein synthesized by cells from the affected 
tissue is collagen (only about 11% of the protein produced 
by control cells). 
CA appear to induce or select fibroblasts 
characterized by enhanced levels of protein synthesis and 
collagen production. This alteration persists through 
several cell replications in vitro in the absence of drug. 
Addition of the drug resulted in reduced levels of 
collagenolytic activity in the culture medium. 
MMP-1 mRNA expression was significantly 
reduced in overgrown compared to normal tissue. GO 
may be explained by a CA-induced inhibition of 
collagenolytic activity within the gingival tissues. The 
fibroblasts and collagen density increased in parallel with 
the severity of the overgrowth. 
Apoptosis plays a critical role in the regulation of 
inflammation and the host immune response; CA 
determined statistical significant increase in keratinocyte 
apoptosis; significantly higher gingival index; significantly 
higher overgrowth scores; significantly more probing sites 
greater than 3 mm. 
A very solid proof about a causal connection 
between PD and CVD is the direct relation between the 
number of teeth still present in third age subjects and 
respectively the average life expectancy [53]. 
In the scientific notifications (included in every 
box of drugs) are mentioned only those AE with such a 
severity that they determined the therapy interruption. 
We must mention, as an example, that GO 
induced by nifedipine is mentioned as being present in 0,5 
% to 83% in those treated (Westside Veterans 
Administration); it worth underline the fact that the high Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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percentages were obtained by periodontologists. The 
important modifications already presented, generated by 
CA can have a very important impact on the 
periodontium, on the cement and, respectively on the 
alveolar bone.  
When a significant destruction and a periodontal 
pouch is present, there is a clear association with many 
inflammatory biomarkers, as hs-CRP, homocysteine, 
fibrinogenemia, PAI-1, D-dimers, Lps  or the pro-
inflammatory cytokines that are increased and can be 
determined at plasmatic and local level. All these 
pathologic changes are part of a productive inflammatory 
process and represent a result of the interaction between 
the pathogen agents and the reactivity of the entire body 
[54-60]. Epithelial hyperplasia that develops not only in 
surface, but also profoundly, can generate epithelial 
islands inside the chorion, by this fact explaining the 
disappearance of contact inhibition, formatting, in this kind 
of cases lesions that are close to the dystrophic-
inflammatory processes and the degenerative ones. 
The important modifications already presented, 
generated by CA can have a very important impact on the 
periodontium, on the cement and on the alveolar bone.  
The precise search and diagnosing GO, is not 
always optimal. That’s why it’s necessary to underline, 
once again, the importance of the periodontal check 
(best option: monthly), made by specialists, beginning a 
few weeks after the initiation of the therapy with CA, till 
after more than 4 years (the period of maximal incidence 
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